Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 14, 2018
Pharmacy Choice - News - Generic Drugs - November 14, 2018

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 54     Next >>     Go To Page:

11/14/18 - 2019 Life Sciences Industry Report from CLSA Shows Strong Growth in Jobs, Investments and Therapeutic Pipeline in California
Directly employed 311,226 Californians with an average wage of $119,000 Generated $178 billion in revenue Projected to attract $7.6 billion in venture capital and $3.9 billion in NIH investment Over 1,300 new medicines in clinical trials. SAN FRANCISCO& SACRAMENTO, Calif.& SAN DIEGO& WASHINGTON California Life Sciences Association, the trade as
11/14/18 - ADIAL PHARMACEUTICALS, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations.
The discussion should be read in conjunction with our unaudited financial statements and the notes presented herein and the audited financial statements and the other information set forth in the Prospectus that forms a part of our Registration Statement on Form S-1, which was filed with the Securities and Exchange Commission pursuant to Rule 424 o
11/14/18 - Biosimilar Market in Europe 2018: Industry Trends, Growth, Demand, Share, Opportunities and Forecast till 2023
Owing to the changing perception towards biosimilars and favorable guidelines laid down by the European Medicines Agency, the biosimilar market in Europe has witnessed a robust growth over the past several years. IMARC Group's latest report, entitled "Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2
11/14/18 - Branded Prescription Drug Prices Continue to Rise - Blue Cross Blue Shield Association Report Reveals
Prescription drug spending among branded specialty and patent-protected drugs continues to outpace generic drugs at $79.5 billion, according to an update to last year's study of medical claims by the Blue Cross Blue Shield Association. At more than $100 billion, prescription drugs represent more than 20 percent of overall healthcare spending for
11/14/18 - CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, today reported financial results for the third quarter and nine months ended September 30, 2018 and provided
11/14/18 - Lidocaine Market Structure Up to 2023 | Key Merchants Pfizer, Teligent, AstraZeneca, Mylan Pharmaceuticals, Taro Pharmaceuticals and More - Asserts MRFR
The Market for Lidocaine Market Will Grow Steady Booming CAGR during the Forecasted Period 2018-2021. To Provide Overview of Key Players and their Strategic Profiling in the Market, Comprehensively Analyzing their Core Competencies, and Drawing a Competitive Landscape for the Market. Some of the key players profiled in the report are AstraZeneca Pl
11/14/18 - Lidocaine Market Structure Up to 2023 | Key Merchants Pfizer, Teligent, AstraZeneca, Mylan Pharmaceuticals, Taro Pharmaceuticals and More Asserts MRFR
"Market Research Future" The Market for Lidocaine Market Will Grow Steady Booming CAGR during the Forecasted Period 2018-2021. To Provide Overview of Key Players and their Strategic Profiling in the Market, Comprehensively Analyzing their Core Competencies, and Drawing a Competitive Landscape for the Market. Some of the key players profiled in the
11/14/18 - Lupin gets USFDA nod for Asthma drug [Sudan Tribune]
The product approved by the United States Food and Drug Administration is a generic version of AstraZeneca Pharmaceuticals LP`s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL, Lupin said in a regulatory filing. Quoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around USD 474.5 million in the US.
11/14/18 - NMPA Accepts Biosimilar New Drug Application for IBI303, a Biosimilar Candidate to Humira(R) (adalimumab) [Syrian Arab News Agency]
Innovent Biologics, Inc., a world-class China- based biopharmaceutical company that develops and commercializes high quality drugs, announced today that National Medical Products Administration has accepted its new drug application for adalimumab biosimilar candidate. IBI303 is a recombinant human anti-TNF- monoclonal antibody independently...
11/14/18 - The Motley Fool Take
Biotech stocks are rarely value stocks, but Celgene is an exception, with a forward-looking price-to-earnings ratio recently below 8. Revlimid makes up more than 60 percent of Celgene's total sales and is expected to generate nearly $10 billion in sales in 2018.. A December 2015 agreement with a handful of generic producers will keep a flood of gen
11/13/18 - 3rd blood pressure drug recalled in recent weeks over impurity
Sandoz, a generic pharmaceutical company that's a division of the Novartis Group, said it's voluntarily recalled losartan potassium hydrochlorothiazide tablets because the pills could contain the impurity N-nitrosodiethylamine. Sandoz said the tablets are manufactured by Lek Pharmaceuticals in Slovenia and the impurity found is a probable...
11/13/18 - Amneal Completes Transition Agreement with Lannett Company to Begin Commercialization of Levothyroxine on December 1st
BRIDGEWATER- Amneal Pharmaceuticals, Inc. today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take over the distribution and marketing of Levothyroxine sodium tablets from Lannett beginning December 1, 2018 through March 23, 2019, ahead of when the Company's previously...
11/13/18 - Biosimilar Market in Europe 2018: Industry Trends, Growth, Demand, Share, Opportunities and Forecast till 2023
"Biosimilar Market in Europe Driven by Ongoing Awareness Initiatives" Owing to the changing perception towards biosimilars and favorable guidelines laid down by the European Medicines Agency, the biosimilar market in Europe has witnessed a robust growth over the past several years. IMARC Group's latest report, entitled " Biosimilar Market in Europe
11/13/18 - Cipla receives final approval for generic version of Roche's Valcyte
Mumbai- Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application for Valganciclovir Tablets 450 mg from the United States Food and Drug Administration. Cipla's Valganciclovir Tablets 450 mg is AB-rated generic therapeutic equivalent version of Roche's Valcyte. Established in 1935, Cipla is a global.
11/13/18 - EpiPen rival from San Diego's Adamis nears market [The San Diego Union-Tribune]
Nov. 12 Challenging the popular but pricey EpiPen, San Diego's Adamis Pharmaceuticals is readying its own emergency allergy medication for sale. Called Symjepi, the product is a pre-filled syringe of epinephrine, used to counteract life-threatening allergic reactions. The launch is being handled by marketing partner Sandoz, a subsidiary of Swiss.
11/13/18 - Generic Sterile Injectable Market Outlook to 2023 3M, Baxter Inc, Fresenius Kabi, Pfizer/Hospira, Novartis/Sandoz, Teva, Hikma, Sun Pharma, Dr. Reddy's, Mylan, AstraZen: Generic Sterile Injectable Market Marketing Channel Development Trend and St
New York, NY 11/13/2018 Over the next five years, Research Reports Inc. projects that Generic Sterile Injectable Market will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.. The generic sterile injectable are FDA approved biologics that are used for the treatment of many diseases and disorde
11/13/18 - Lannett Enters Into Agreement with Amneal Pharmaceuticals for Levothyroxine
PHILADELPHIA- Lannett Company, Inc. today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. with regard to Levothyroxine Sodium Tablets USP. Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.
11/13/18 - NMPA Accepts Biosimilar New Drug Application for IBI303, a Biosimilar Candidate to Humira(R) (adalimumab)
Innovent Biologics, Inc., a world-class China- based biopharmaceutical company that develops and commercializes high quality drugs, announced today that National Medical Products Administration has accepted its new drug application for adalimumab biosimilar candidate. IBI303 is a recombinant human anti-TNF- monoclonal antibody independently...
11/13/18 - Teligent, Inc. Announces Third Quarter 2018 Results
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2018.. Total revenue was driven primarily by $11.4 million of sales generated by our U.S. generic topical and injectable pharmaceutical products, an increase of 39% over the same quarter in
11/13/18 - Topical Pain Management Therapeutics in Sports Medicine Market Is Projected to Expand at a CAGR of 8.9% from 2017 to 2025
Albany, NY 11/13/2018 The pain management therapeutics market witnesses an exponential presence of generic medicines. Given the scenario, Transparency Market Research predicts the entry of several small and medium scale generic drug producers, making the global topical pain management therapeutics in sports medicine market highly saturated.
11/12/18 - Acinetobacter Infections Treatment Market Outlook, Opportunity and Demand Analysis, Forecast 2024
Albany, NY 11/12/2018 Global Acinetobacter Infections Treatment Market: Overview. Acinetobacter baumannii is a rod shaped gram-negative coccobacillus bacterium. This bacterium is becoming an important cause of hospital derived bacterial infection affecting people with weakened immune system.
11/12/18 - Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
Amneal Pharmaceuticals, Inc. today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take over the distribution and marketing of Levothyroxine sodium tablets from Lannett beginning December 1, 2018 through March 2 3, 2019, ahead of when the Company's previously announced 10-
11/12/18 - CDMOs Using Single-use and IIoT Solutions Will Reduce Costs and Enhance Production Efficiency
"With the growing patent cliffs in branded biologics, biosimilars are set to account for almost 15 percent to 20 percent of the business of Bio-CDMOs, thus presenting considerable opportunities in production and co-development," said Unmesh Lal, Program Manager, Transformational Health. Frost& Sullivan's recent analysis, Global Biologics Contract..
11/12/18 - Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2019 Ended September 30, 2018 and Provides Conference Call Information
NORTHVALE- Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the second quarter of fiscal year 2019 ended September 30, 2018. Elite currently has five additional ANDAs filed with the FDA, will be launching three additional products shortly through our
11/12/18 - Kadmon Provides Business Update and Reports Third Quarter 2018 Financial Results
NEW YORK- Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the third quarter of 2018.. FDA Breakthrough Therapy Designation Granted to KD025- In October 2018, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to KD025, the Company's ROCK2 inhibitor, for the treatm
Articles(s): 1 - 25 of 54     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415